Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

Otto Metzger-Filho, Marion Procter, Evandro de Azambuja, Brian Leyland-Jones, Richard D Gelber, Mitchell Dowsett, Sherene Loi, Kamal S Saini, David Cameron, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Christian Jackisch, Richard Bell, Christos Sotiriou, Giuseppe Viale, Martine Piccart-Gebhart

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial.
Original languageEnglish
Pages (from-to)1954-60
Number of pages7
JournalJournal of Clinical Oncology
Volume31
Issue number16
DOIs
Publication statusPublished - 1 Jun 2013

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Invasiveness
  • Proportional Hazards Models
  • Receptor, erbB-2
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Survival Analysis
  • Treatment Outcome
  • Tumor Markers, Biological

Fingerprint

Dive into the research topics of 'Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial'. Together they form a unique fingerprint.

Cite this